Inhibition of EGFR Signaling: All Mutations Are Not Created Equal
Author Information
Author(s): Adi F. Gazdar, John D. Minna
Primary Institution: University of Texas Southwestern Medical Center
Hypothesis
Different EGFR mutations in lung cancer respond differently to specific inhibitors.
Conclusion
All recognized classes of EGFR mutations in lung cancers are activating, but mutations involving exon 20 show a different response pattern to TKIs compared to other mutations.
Supporting Evidence
- Activating mutations in the EGFR gene are found in a subset of non-small-cell lung cancer, especially adenocarcinomas.
- Different classes of EGFR mutations may vary in their clinicopathological correlations and responsiveness to TKIs.
- Cells with the deletion mutant and the point mutation L858R were inhibited by TKIs, while the exon 20 insertion mutation was resistant.
Takeaway
Some changes in a gene called EGFR can make lung cancer cells behave differently, and some treatments work better for certain changes than others.
Methodology
The study used in vitro model systems to demonstrate the transforming abilities of various EGFR mutations.
Limitations
Not all resistant tumors have an identified molecular basis, and multiple factors may influence the response to TKIs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website